Gamma-aminobutyric acid receptor subunit beta-3 (GABRB3) (GABRB3)

Gamma-aminobutyric acid receptor subunit beta-3 (GABRB3) containing receptors are a critical subtype of ionotropic GABAA receptors that mediate fast inhibitory neurotransmission in the central nervous system (NIH, 2023). The beta-3 subunit is essential for the assembly of functional pentameric receptor complexes and is widely expressed in the cortex, hippocampus, and thalamus (Guide to Pharmacology). These receptors contribute to both synaptic (phasic) and extrasynaptic (tonic) inhibition, which are vital for regulating neuronal excitability and maintaining thalamocortical rhythms (NIH, 2020). During embryonic development, the beta-3 subunit plays a key role in neuronal proliferation, migration, and differentiation (Wikipedia). Genetic abnormalities in the GABRB3 gene, such as deletions or missense mutations, are strongly associated with neurodevelopmental disorders and epilepsies, including Angelman syndrome, autism spectrum disorder, and Lennox-Gastaut syndrome (NIH, 2023; Epilepsy Genetics). Pharmacologically, beta-3 containing receptors are primary targets for intravenous anesthetics like etomidate and propofol, which act as positive allosteric modulators with selectivity for beta-2/3-containing subtypes (Wikipedia, 2025). Furthermore, emerging research indicates that the beta-3 subunit is overexpressed in triple-negative breast cancer, where it may promote tumor cell proliferation and migration, suggesting its potential as a non-neuronal therapeutic target (PubMed, 2023).

Other names

GABRB3GABA(A) receptor subunit beta-3GABAA receptor beta-3 subunitGamma-aminobutyric acid type A receptor subunit beta 3Beta-3 subunit of the GABAA receptor

Positive allosteric modulation of the GABAA receptor chloride channel and direct allosteric agonism at higher concentrations (Wikipedia, 2025; NIH, 2015).